Bank of New York Mellon
KZR

Bank of New York Mellon’s Kezar Life Sciences KZR Stock Holding History

Bank of New York Mellon’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,426
Closed -$193K – 4207
2024
Q1 		$193K Sell
21,426
-796
-4% -$7.25K ﹤0.01% 3941
2023
Q4 		$211K Sell
22,222
-4,162
-16% -$36.6K ﹤0.01% 3939
2023
Q3 		$314K Buy
26,384
+440
+2% +$7.8K ﹤0.01% 3784
2023
Q2 		$636K Buy
25,944
+7,928
+44% +$206K ﹤0.01% 3467
2023
Q1 		$564K Sell
18,016
-204
-1% -$11.8K ﹤0.01% 3433
2022
Q4 		$1.28M Buy
18,220
+35
+0.2% +$2.6K ﹤0.01% 3076
2022
Q3 		$1.57M Buy
18,185
+3,387
+23% +$329K ﹤0.01% 2987
2022
Q2 		$1.22M Sell
14,798
-4,301
-23% -$379K ﹤0.01% 3110
2022
Q1 		$3.17M Sell
19,099
-84
-0.4% -$12.1K ﹤0.01% 2679
2021
Q4 		$3.21M Buy
19,183
+6,850
+56% +$773K ﹤0.01% 2711
2021
Q3 		$1.07M Buy
12,333
+1,114
+10% +$73.7K ﹤0.01% 3361
2021
Q2 		$609K Buy
11,219
+115
+1% +$6.53K ﹤0.01% 3680
2021
Q1 		$661K Sell
11,104
-162
-1% -$9.47K ﹤0.01% 3539
2020
Q4 		$588K Buy
11,266
+8
+0.1% +$445 ﹤0.01% 3536
2020
Q3 		$545K Buy
11,258
+1,086
+11% +$51.9K ﹤0.01% 3450
2020
Q2 		$527K Buy
10,172
+532
+6% +$26.8K ﹤0.01% 3441
2020
Q1 		$420K Buy
9,640
+4,833
+101% +$197K ﹤0.01% 3459
2019
Q4 		$192K Sell
4,807
-152
-3% -$4.68K ﹤0.01% 3926
2019
Q3 		$162K Sell
4,959
-251
-5% -$12.1K ﹤0.01% 3942
2019
Q2 		$402K Buy
5,210
+1,875
+56% +$292K ﹤0.01% 3704
2019
Q1 		$592K Buy
3,335
+1,593
+91% +$314K ﹤0.01% 3470
2018
Q4 		$411K Buy
+1,742
New +$426K ﹤0.01% 3583

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Bank of New York Mellon's KZR Position: Q2 2024 in Review

Bank of New York Mellon sold out of Kezar Life Sciences (KZR) in Q2 2024, closing a stake of 21,426 shares — an estimated $193K sold.

Bank of New York Mellon first reported a position in KZR in Q4 2018 and held it in 22 quarters. The position peaked at $3.21M in Q4 2021. 81 funds tracked by Wall St. Rank hold KZR as of Q2 2024.

  • Bank of New York Mellon reported no remaining Kezar Life Sciences position as of Q2 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 21,426 Kezar Life Sciences shares in Q2 2024, an estimated $193K.
  • Bank of New York Mellon first reported a position in Kezar Life Sciences in Q4 2018 and held it in 22 quarters.
  • Bank of New York Mellon's Kezar Life Sciences position peaked at $3.21M in Q4 2021.
  • 81 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2024.

Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.